Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Feb 08, 2026
Intercontinental Exchange (ICE) Q4 2025 Earnings Recap: Record Revenues Drive 14% EPS Growth

Intercontinental Exchange (ICE) Q4 2025 Earnings Recap: Record Revenues Drive 14% EPS Growth

Key Takeaways

  • ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.

  • Adjusted diluted EPS of $1.71 exceeded consensus estimates of $1.68, with full-year adjusted EPS of $6.95, up 14% from 2024.

  • Exchanges segment revenues reached $1.4 billion (+10%), led by 15% growth in Energy volumes extending into January 2026.

  • Mortgage Technology revenues rose 5% to $532 million, with transaction revenues up 20%; Fixed Income & Data Services grew 5%.

  • ICE returned $2.4 billion to shareholders in 2025 through $1.3 billion in buybacks and over $1.1 billion in dividends; leverage reduced to 3.0x.

  • 2026 guidance anticipates 4–5% growth in adjusted operating expenses, $740–790 million in capex, and mid-single-digit recurring revenue growth across segments.

Earnings Context and Why It Matters

ICE, operator of the New York Stock Exchange and a global leader in derivatives, data, and mortgage technology, delivered Q4 results highlighting the resilience of its diversified “all-weather” business model. Record energy trading volumes, robust fixed income scaling, and mortgage workflow efficiency supported strong top-line growth. Investors view ICE’s diversified revenue streams—spanning exchanges (≈55% of revenues), data services, and mortgage tech—as stabilizing amid market volatility, while strategic technology investments, including AI initiatives, position the company for long-term growth. Strong cash flows also enabled substantial capital returns, reinforcing shareholder value.

Reported Results vs. Expectations

ICE beat consensus forecasts with Q4 2025 net revenues of $2.5 billion (+8% YoY, +7% constant currency) and adjusted EPS of $1.71 (consensus $1.68), up 13% from $1.52 in Q4 2024. GAAP diluted EPS was $1.49, with net income attributable to ICE of $851 million.

Segment performance included:

  • Exchanges: $1.4 billion (+10%), driven by Energy (+15%), Cash Equities/Options (+5%), and Data/Connectivity (+16%).

  • Fixed Income & Data Services: $608 million (+5%), analytics +6%.

  • Mortgage Technology: $532 million (+5%), with transaction revenue up 20% despite recurring stability.

For full-year 2025, ICE posted:

  • Net revenues: $9.9 billion (+7%)

  • Adjusted EPS: $6.95 (+14%)

  • Adjusted operating income: $6.0 billion (60% margin)

  • Adjusted free cash flow: $4.2 billion (+16%)

  • GAAP net income: $3.3 billion

Market Reaction and Investor Sentiment

ICE shares rose 1.8–4.5% in pre-market and early trading to ~$168, reflecting investor approval of the revenue and EPS beats, strong trading volumes, and disciplined capital allocation. Positive sentiment was further supported by:

  • Record Energy volumes extending into January 2026

  • Black Knight synergies reaching $230 million

  • Continued share repurchases and dividend payments

Analysts maintained buy ratings, highlighting the strength of ICE’s diversified model even amid mortgage technology headwinds from Encompass adjustments.

Forward Outlook and Key Factors to Monitor

ICE enters 2026 with momentum from January’s record trading activity—average daily volume up 23% YoY and open interest up 18%, particularly in energy (ADV +27%). Guidance includes:

  • Adjusted operating expenses: +4–5% to $4.075–4.140 billion

  • Capex: $740–790 million (including AI and data center investments)

  • Effective tax rate: 24–26%

  • Recurring revenue growth: mid-single-digits in Exchanges and Fixed Income & Data Services; low-to-mid single digits in Mortgage Technology

Investors should monitor:

  • Commodity, rates, and equity trading volumes amid geopolitical and rate dynamics

  • Fixed income analytics adoption and mortgage workflow trends (Encompass implementations: 90 deals in 2025)

  • Execution on Black Knight synergies ($275 million targeted by 2028)

  • NYSE listings pipeline ($25 billion IPO capital in 2025)

  • ETF AUM growth (up 20% to $794 billion)

  • Innovations like AI-powered sentiment tools and Treasury clearing solutions

Cost discipline, FX impacts, and macro volatility in energy, power, and environmental markets remain pivotal for margin expansion and free cash flow growth. ICE’s diversified model and strong cash generation provide a buffer against short-term headwinds while supporting long-term strategic investments.
The Swing Trader: Search for Dips and Trend Reversal, 60 min, (TA&FA) is a Tickeron AI trading bot tailored for ICE.

Disclaimers and Limitations

Related Ticker: ICE

ICE in upward trend: 10-day moving average broke above 50-day moving average on July 24, 2026

The 10-day moving average for ICE crossed bullishly above the 50-day moving average on July 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 06, 2026. You may want to consider a long position or call options on ICE as a result. In of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ICE just turned positive on July 02, 2026. Looking at past instances where ICE's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

ICE moved above its 50-day moving average on July 22, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ICE advanced for three days, in of 336 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 316 cases where ICE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ICE moved out of overbought territory on July 31, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where ICE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ICE broke above its upper Bollinger Band on July 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ICE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.834) is normal, around the industry mean (5.457). P/E Ratio (21.044) is within average values for comparable stocks, (25.155). Projected Growth (PEG Ratio) (2.738) is also within normal values, averaging (2.912). Dividend Yield (0.013) settles around the average of (0.018) among similar stocks. P/S Ratio (6.345) is also within normal values, averaging (7.914).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are CME Group (NASDAQ:CME).

Industry description

The financial publishing /services sector includes companies that provide informational products and services that are of value to investors, financial/analytics professionals and other interested readers. The products include real-time stock quotes, financial news and analyses. Think S&P Global, Inc., Moody`s Corporation, Thomson-Reuters Corp and IHS Markit Ltd. Information is critical in making financial or investment decisions, and what makes this industry’s output relevant at all times, across various economic conditions.

Market Cap

The average market capitalization across the Financial Publishing/Services Industry is 38.72B. The market cap for tickers in the group ranges from 2.12M to 121.61B. SPGI holds the highest valuation in this group at 121.61B. The lowest valued company is BTOG at 2.12M.

High and low price notable news

The average weekly price growth across all stocks in the Financial Publishing/Services Industry was -2%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 3%. DTCX experienced the highest price growth at 7%, while COIN experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Financial Publishing/Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -30% and the average quarterly volume growth was -71%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 54
SMR Rating: 56
Profit Risk Rating: 81
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
ICE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

an operator of online global electronic marketplace for trading in futures and over-the-counter commodities

Industry FinancialPublishingServices

Profile
Details
Industry
Investment Banks Or Brokers
Address
5660 New Northside Drive
Phone
+1 770 857-4700
Employees
13222
Web
https://www.theice.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.